Oligonucleotide Sequences Required for Natural Killer Cell Activation

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1992 Nov 1

PMID 1483927

Citations 23

Authors

E Kuramoto

O Yano

Y Kimura

M Baba

T Makino

S Yamamoto

T Yamamoto

T Kataoka

T Tokunaga

Affiliations

Soon will be listed here.

Abstract

Based on the previous finding that certain 30-mer single-stranded oligodeoxyribonucleotides (oligonucleotides) having particular 6-mer palindromic sequences could induce interferon-alpha and -gamma, and enhance natural killer activity, the present study was carried out to clarify the entire relationship between the activity and the sequence of 30-mer oligonucleotides. The results indicated that the activity depended critically on the presence of particular palindromic sequences including the 5'-CG-3' motif(s). The size and the number of palindromes as well as the extra-palindromic sequences also influenced the activity. An oligonucleotide with a 10-mer palindrome and extra-palindromic oligoguanylate sequences showed the strongest activity among the oligonucleotides tested.

Citing Articles

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Batista-Duharte A, Sendra L, Herrero M, Tellez-Martinez D, Carlos I, Alino S Biomolecules. 2020; 10(2).

PMID: 32079263 PMC: 7072586. DOI: 10.3390/biom10020316.

In vivo cancer vaccination: Which dendritic cells to target and how?.

Lai-Lai Chiang C, Kandalaft L Cancer Treat Rev. 2018; 71:88-101.

PMID: 30390423 PMC: 6295330. DOI: 10.1016/j.ctrv.2018.10.012.

CpG oligodeoxynucleotides as mucosal adjuvants.

Iho S, Maeyama J, Suzuki F Hum Vaccin Immunother. 2015; 11(3):755-60.

PMID: 25751765 PMC: 4514178. DOI: 10.1080/21645515.2014.1004033.

A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity.

Maeyama J, Takatsuka H, Suzuki F, Kubota A, Horiguchi S, Komiya T PLoS One. 2014; 9(2):e88846.

PMID: 24586411 PMC: 3933336. DOI: 10.1371/journal.pone.0088846.

Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Tom J, Mancini R, Esser-Kahn A Chem Commun (Camb). 2013; 49(83):9618-20.

PMID: 24022092 PMC: 4399865. DOI: 10.1039/c3cc45468a.

References

Ornstein R, Rein R . An optimized potential function for the calculation of nucleic acid interaction energies I. base stacking. Biopolymers. 2014; 17(10):2341-60. DOI: 10.1002/bip.1978.360171005. View

Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y . Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984; 72(4):955-62. View

Shimada S, Yano O, Tokunaga T . In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res. 1986; 77(8):808-16. View

Bock L, Griffin L, Latham J, Vermaas E, Toole J . Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature. 1992; 355(6360):564-6. DOI: 10.1038/355564a0. View

Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T . Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992; 148(12):4072-6. View

Mitchell P, SIGEL H . A proton nuclear-magnetic-resonance study of self-stacking in purine and pyrimidine nucleosides and nucleotides. Eur J Biochem. 1978; 88(1):149-54. DOI: 10.1111/j.1432-1033.1978.tb12432.x. View

Kataoka T, Yamamoto S, Yamamoto T, Kuramoto E, Kimura Y, Yano O . Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG. Jpn J Cancer Res. 1992; 83(3):244-7. PMC: 5918807. DOI: 10.1111/j.1349-7006.1992.tb00094.x. View

Shimada S, Yano O, Inoue H, Kuramoto E, Fukuda T, Yamamoto H . Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst. 1985; 74(3):681-8. View

Tinoco Jr I, Borer P, Dengler B, Levin M, Uhlenbeck O, Crothers D . Improved estimation of secondary structure in ribonucleic acids. Nat New Biol. 1973; 246(150):40-1. DOI: 10.1038/newbio246040a0. View

10.

Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T . DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 1992; 36(9):983-97. DOI: 10.1111/j.1348-0421.1992.tb02102.x. View

11.

Messina J, Gilkeson G, Pisetsky D . Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol. 1991; 147(6):1759-64. View

12.

Kuramoto E, Toizumi S, Shimada S, Tokunaga T . In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. Microbiol Immunol. 1989; 33(11):929-40. DOI: 10.1111/j.1348-0421.1989.tb00980.x. View

13.

Yamamoto S, Kuramoto E, Shimada S, Tokunaga T . In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res. 1988; 79(7):866-73. PMC: 5917587. DOI: 10.1111/j.1349-7006.1988.tb00049.x. View

14.

Tokunaga T, Yano O, Kuramoto E, Kimura Y, Yamamoto T, Kataoka T . Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells. Microbiol Immunol. 1992; 36(1):55-66. DOI: 10.1111/j.1348-0421.1992.tb01642.x. View